Xbrane Biopharma: SEK240m directed issue with positive implications - Redeye

Redeye comments on Xbrane following its SEK240m directed share issue targeting both institutional and industrial capital. The net proceeds bridge the funding gap, and we view this as a strong outcome among the possible financing scenarios - adjusting our base case accordingly.

Länk till analysen i sin helhet: https://www.redeye.se/research/1114861/xbrane-biopharma-sek240m-directed-issue-with-positive-implications?utm_source=finwire&utm_medium=RSS